- Home
- ADBE vs AZN Comparison
ADBE vs AZN Comparison
Compare ADBE & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADBE
- AZN
- Stock Information
- Founded
- ADBE 1982
- AZN 1992
- Country
- ADBE United States
- AZN United Kingdom
- Employees
- ADBE N/A
- AZN N/A
- Industry
- ADBE Computer Software: Prepackaged Software
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- ADBE Technology
- AZN Health Care
- Exchange
- ADBE Nasdaq
- AZN Nasdaq
- Market Cap
- ADBE 221.2B
- AZN 234.5B
- IPO Year
- ADBE 1986
- AZN 1993
- Fundamental
- Price
- ADBE $512.15
- AZN $65.63
- Analyst Decision
- ADBE Buy
- AZN Buy
- Analyst Count
- ADBE 27
- AZN 10
- Target Price
- ADBE $605.96
- AZN $88.80
- AVG Volume (30 Days)
- ADBE 2.7M
- AZN 8.6M
- Earning Date
- ADBE 12-11-2024
- AZN 11-12-2024
- Dividend Yield
- ADBE N/A
- AZN 2.26%
- EPS Growth
- ADBE 6.28
- AZN 9.79
- EPS
- ADBE 11.81
- AZN 4.15
- Revenue
- ADBE $20,947,000,000.00
- AZN $51,206,000,000.00
- Revenue This Year
- ADBE $12.67
- AZN $17.69
- Revenue Next Year
- ADBE $10.95
- AZN $7.95
- P/E Ratio
- ADBE $43.35
- AZN $31.28
- Revenue Growth
- ADBE 10.91
- AZN 13.81
- 52 Week Low
- ADBE $433.97
- AZN $60.47
- 52 Week High
- ADBE $638.25
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- ADBE 54.66
- AZN 37.08
- Support Level
- ADBE $493.10
- AZN $62.88
- Resistance Level
- ADBE $539.92
- AZN $64.13
- Average True Range (ATR)
- ADBE 13.85
- AZN 1.19
- MACD
- ADBE 1.10
- AZN 0.24
- Stochastic Oscillator
- ADBE 53.29
- AZN 60.00
About ADBE Adobe Inc.
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.